Sildenafil Tablet
Product Images NDC 71335-1963

7 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 71335-1963). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Sildenafil Structure)

Structure (Sildenafil Structure)
Chemical structure of Sildenafil as shown in the molecular diagram. The image includes rings, alkyl groups, sulfonamide, and carboxylic acid moieties consistent with the Sildenafil molecule's known structure.*
FDA Label Image

Figure1 (Sildenafil Fig1)

Figure1 (Sildenafil Fig1)
A forest plot chart showing fold change and 90% confidence intervals for interactions between Sildenafil and various drugs or oral contraceptives. The chart compares maximum concentration (Cmax) and area under the curve (AUC) values relative to Sildenafil alone, indicating recommendations such as no dose adjustment or coadministration not recommended.*
FDA Label Image

Figure2 (Sildenafil Fig2)

Figure2 (Sildenafil Fig2)
A horizontal forest plot showing fold change and 95% confidence intervals of various interacting drugs on the pharmacokinetics of sildenafil tablets 20 mg by Bryant Ranch Prepack. It compares the area under the curve (AUC) or maximum concentration (Cmax) changes relative to sildenafil alone, along with corresponding dosage adjustment recommendations for each interacting drug.*
FDA Label Image

Figure3 (Sildenafil Fig3)

Figure3 (Sildenafil Fig3)
A line graph displaying change from baseline in meters over a 12-week study for different doses of Sildenafil (20 mg, 40 mg, 80 mg TID) and placebo. The y-axis measures change from baseline, while the x-axis shows weeks 4, 8, and 12. Data points include error bars, comparing the effects of Sildenafil doses versus placebo across the study period.*
FDA Label Image

Figure4 (Sildenafil Fig4)

Figure4 (Sildenafil Fig4)
A chart showing placebo-corrected change in 6-minute walk distance (meters) for Sildenafil 20 mg TID versus placebo. The chart compares results across various subgroups including baseline walk distance, etiology, pulmonary hypertension class, gender, age, mean PAP, and PVRI. Data points with confidence intervals visually represent the efficacy of Sildenafil in each subgroup.*
FDA Label Image

Figure5 (Sildenafil Fig5)

Figure5 (Sildenafil Fig5)
A line graph comparing the percentage of subjects without a clinically worsening event over days from randomization between placebo and Sildenafil groups. The x-axis represents days from randomization (0 to 112), and the y-axis shows the percentage without worsening (0 to 100%). The Sildenafil group maintains a higher percentage without worsening compared to placebo throughout the period.*
FDA Label Image

Label (Lbl713351963)

Label (Lbl713351963)
Sildenafil Citrate 20 mg tablet label showing a white round tablet, packaged by Bryant Ranch Prepack in Burbank, CA. The label notes comparison to Revatio 20 mg tablet by Ajanta Pharma Limited. Storage instructions specify room temperature 20°-25°C (68°-77°F), with warnings to keep out of reach of children. The NDC is 71335-1963-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.